News
Kymera Therapeutics Reveals Preclinical Data on Cancer-Fighting Drug KT-333 at AACR Meeting
8 Apr 24
News
Truist Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $54
1 Mar 24
News, Price Target, Analyst Ratings
Piper Sandler Maintains Overweight Rating for Kymera Therapeutics: Here's What You Need To Know
27 Feb 24
Analyst Ratings
Piper Sandler Maintains Overweight on Kymera Therapeutics, Raises Price Target to $56
27 Feb 24
News, Price Target, Analyst Ratings
Breaking Down Kymera Therapeutics: 4 Analysts Share Their Views
23 Feb 24
Analyst Ratings
Kymera Therapeutics Q4 EPS $(0.25) Beats $(0.40) Estimate, Sales $47.88M Beat $41.96M Estimate
22 Feb 24
Earnings, News
Earnings Scheduled For February 22, 2024
22 Feb 24
Earnings
Wolfe Research Initiates Coverage On Kymera Therapeutics with Peer Perform Rating
15 Feb 24
News, Initiation, Analyst Ratings
Press releases
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
8 Mar 24
Press Releases, General
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
28 Feb 24
News, Health Care, Press Releases